Plazomicin sulfate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for plazomicin sulfate and what is the scope of freedom to operate?
Plazomicin sulfate
is the generic ingredient in one branded drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Plazomicin sulfate has twenty-eight patent family members in twenty-one countries.
Three suppliers are listed for this compound.
Summary for plazomicin sulfate
| International Patents: | 28 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Patent Applications: | 4 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for plazomicin sulfate |
| DailyMed Link: | plazomicin sulfate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for plazomicin sulfate
Generic Entry Date for plazomicin sulfate*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for plazomicin sulfate
US Patents and Regulatory Information for plazomicin sulfate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 9,266,919 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 8,383,596 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 9,688,711 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for plazomicin sulfate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 101868472 | Antibacterial aminoglycoside analogs | ⤷ Subscribe |
| Canada | 2706369 | ANALOGUES D'AMINOGLYCOSIDES ANTIBACTERIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS) | ⤷ Subscribe |
| China | 103360440 | Antibacterial aminoglycoside analogs | ⤷ Subscribe |
| South Korea | 101296099 | ⤷ Subscribe | |
| Portugal | 2217610 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
